Becton Dickinson Change in Assets/Liabilities 2010-2025 | BDX
Becton Dickinson annual/quarterly change in assets/liabilities history and growth rate from 2010 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
- Becton Dickinson change in assets/liabilities for the quarter ending June 30, 2025 was $-1.050B, a 432.99% increase year-over-year.
- Becton Dickinson change in assets/liabilities for the twelve months ending June 30, 2025 was $-2.505B, a 791.99% decline year-over-year.
- Becton Dickinson annual change in assets/liabilities for 2024 was $0.061B, a 92.78% decline from 2023.
- Becton Dickinson annual change in assets/liabilities for 2023 was $0.845B, a 332.14% decline from 2022.
- Becton Dickinson annual change in assets/liabilities for 2022 was $-0.364B, a 256.22% decline from 2021.
Becton Dickinson Annual Change in Assets/Liabilities
(Millions of US $) |
| 2024 |
$61 |
| 2023 |
$845 |
| 2022 |
$-364 |
| 2021 |
$233 |
| 2020 |
$441 |
| 2019 |
$1,213 |
| 2018 |
$-46 |
| 2017 |
$-366 |
| 2016 |
$90 |
| 2015 |
$-69 |
| 2014 |
$-120 |
| 2013 |
$-60 |
| 2012 |
$102 |
| 2011 |
$-239 |
| 2010 |
$-34 |
| 2009 |
$-22 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$57.228B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
